Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Subcutaneous CT-P6 vs Herceptin in Healthy Males
NCT06687928Phase 1Completed
- Sponsor
- Celltrion
- Start
- Mar 2025
- Primary completion
- Aug 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of trastuzumab in breast cancer (2 arms), sponsored by Celltrion. Primary endpoint: Pharmacokinetic similarity at Day 64. Started Mar 2025; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06687928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06687928.